Adagene Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Adagene Inc. | ADAG - NASDAQ |
$17.00-$19.00 | $19.00 | $20.40 | 7.4 million ADSs | 2/9/2021 |
| Goldman Sachs, Morgan Stanley, Jefferies | ||||||
Co-Manager(s): China Renaissance | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-01-19 Terms Added 2021-02-03 | ||||||
Adagene Inc. Quote & Chart - Click for current quote - ADAG
IPO Boutique aggregates information on public companies and private companies, such as "ADAG" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Adagene Inc. (adapted from Adagene Inc. prospectus):
They are a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ADAG" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.